Results 301 to 310 of about 168,140 (338)

Combining immunotherapy with radiation therapy in thoracic oncology [PDF]

, 2018
Badiyan, Shahed N, Chilukuri, Srinivas, Chuong, Michael D, Glass, Erica, Mohindra, Pranshu, Onyeuku, Nasarachi E, Remick, Jill, Rice, Stephanie R, Roach, Michael C, Simone, Charles B, II   +9 more
core   +1 more source

Comprehensive Update on Implants in Patients With Head and Neck Cancer (2021–2024): Systematic Review and Meta‐Analysis of the Impact of Radiotherapy and Chemotherapy on Implant Survival

Clinical Oral Implants Research, EarlyView.
ABSTRACT Objectives This study aimed to investigate implant outcomes in patients with head and neck cancer undergoing radiotherapy or chemotherapy by incorporating the latest research findings. Methods The present review was conducted to update the focused question: What is the survival rate of implants placed in patients with head and neck cancer ...
Shengchi Fan, Leonardo Diaz, Gustavo Sáenz‐Ravello, Eduard Valmaseda‐Castellon, Bilal Al‐Nawas, Eik Schiegnitz   +5 more
wiley   +1 more source

A comparison of the survival outcome of paclitaxel liposome-based chemoradiotherapy with or without rhEndostatin for unresectable esophageal squamous cell carcinoma: a retrospective study. [PDF]

Discov Oncol
Zhu M, Liao J, Wei M, Huang S, Xu J, Li Q, Pan X.   +6 more
europepmc   +1 more source

Circulating Tumour DNA as a Complementary Tool for Treatment Evaluation in HPV‐Associated Head and Neck Squamous Cell Carcinoma: An Observational Cohort Study

Clinical Otolaryngology, EarlyView.
ABSTRACT Objectives HPV‐positive oropharyngeal squamous cell carcinoma (OPSCC) and head and neck carcinoma of unknown primary (HNCUP) are increasing. Despite good prognosis, recurrence rates range from 10% to 25%. Surveillance with clinical controls and imaging is not always reliable.
Anna Oldaeus Almerén, Max Waenerlund, Fredrik Landström, Mathias von Beckerath, Alvida Qvick, Jessica Carlsson, Gisela Helenius   +6 more
wiley   +1 more source

Factors affecting survival prognosis of patients with rectal cancer after neoadjuvant chemoradiotherapy. [PDF]

Front Oncol
Li B, Han J, Wang F, Yu B, Wang G, Yang F.   +5 more
europepmc   +1 more source

Herbal Medicine for Colorectal Cancer Treatment: Molecular Mechanisms and Clinical Applications

Cell Proliferation, EarlyView.
Colorectal cancer is a prevalent gastrointestinal tumour and the second deadliest cancer worldwide, affecting approximately 10% of all cancers and cancer‐related deaths. Current clinical methods for treating CRC cause gastrointestinal abnormalities and myelosuppression.
Zuqing Su, Yanlin Li, Zihao Zhou, Bing Feng, Haiming Chen, Guangjuan Zheng   +5 more
wiley   +1 more source

Adipose tissue from oesophageal adenocarcinoma patients is differentially affected by chemotherapy and chemoradiotherapy regimens altering immune cell phenotype and cancer cell metabolism. [PDF]

Transl Oncol
O'Connell F, Mylod E, Donlon NE, Davern M, Butler C, O'Connor N, Menon MS, Donohoe CL, Ravi N, Doherty DG, Dunne MR, Reynolds JV, Roche HM, O'Sullivan J.   +13 more
europepmc   +1 more source

Sex Differences in Health‐Related Quality of Life in Patients With Head and Neck Cancer—A Prospective Study

International Journal of Dental Hygiene, EarlyView.
ABSTRACT Objective To analyse sex differences in health‐related quality of life (HRQL) before, during and up to 3 months posttreatment of head and neck cancer, and to examine the importance of salivary secretion rate for HRQL posttreatment. Methods Patients were recruited before starting curative oncologic treatment.
Niklas Bohm, Charlott Karlsson, Caterina Finizia, Jessica Skoogh Andersson, Annica Almståhl   +4 more
wiley   +1 more source

Real-World Assessment of Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study. [PDF]

Cancer Med
Yan J, Liu Z, Chen H, Sun X, Ge X, Xia X.   +5 more
europepmc   +1 more source